Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TTS 2022)
September 15, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-1500 Treatment Prevents Organ Rejection and Preserves Function for Both Allograft and Xenograft Transplants in Animal Studies CHATHAM, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Tonix...
Tonix Pharmaceuticals Announces Oral Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) at the International Congress of The Transplantation Society (TTS 2022)
September 06, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced three oral...
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID
August 22, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Results from Planned Interim Analysis Expected First Half 2023 Long COVID Afflicts More Than 30% of Patients Following Infection with SARS-CoV-2, the Virus that Causes COVID-19, and is Expected to...
Tonix Pharmaceuticals to Present at the 2022 Virtual Q3 Investor Summit
August 09, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., Chief...
Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
August 08, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Phase 1 Study of TNX-801, a Vaccine in Development for the Prevention of Monkeypox and Smallpox, Expected to Initiate in First Half 2023 in Kenya; the U.S. has Declared Monkeypox a Public Health...
Tonix Pharmaceuticals Receives Federal Grant from the National Institute on Drug Abuse (NIDA) to Advance Development of TNX-1300 as a Treatment for Cocaine Intoxication
August 02, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
There is No FDA-Approved Product for Cocaine Intoxication TNX-1300 Has Been Granted Breakthrough Therapy Designation by the FDA Phase 2 Single-Blind, Placebo-Controlled, Potential Pivotal Study...
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain
August 01, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
New patent expected to expire in 2036 Phase 2 Study for Prevention of Migraine Headache Expected to Start Second Half 2022 CHATHAM, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals...
Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection
July 28, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Phase 1 Clinical Study Expected to be Initiated in Kenya in the First Half of 2023 World Health Organization Has Declared Monkeypox a Global Health Emergency CHATHAM, N.J., July 28, 2022 (GLOBE...
Tonix Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and Development
July 25, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the...
Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive Disorder
July 11, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Naloxone-Free Formulation of Tianeptine is an Extended-Release Tablet that Includes Inactive Ingredients and Compression Properties Designed to Confer Abuse Deterrence Once-Daily Tablet Formulation...